Journal article
Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease
Rheumatology, Vol.63(3), pp.639-647
03/01/2024
DOI: 10.1093/rheumatology/kead280
PMCID: PMC10907814
PMID: 37294870
Abstract
Objectives: To investigate the course of interstitial lung disease (ILD) and the effects of nintedanib in patients with limited cutaneous systemic sclerosis (lcSSc).
Methods: In the SENSCIS trial, patients with SSc-ILD were randomised to receive nintedanib or placebo. Patients who completed the SENSCIS trial were eligible to enter SENSCIS-ON, in which all patients received open-label nintedanib.
Results: Among 277 patients with lcSSc treated in the SENSCIS trial, the rate (SE) of decline in FVC (mL/year) over 52 weeks was -74.5 (19.2) in the placebo group and -49.1 (19.8) in the nintedanib group (difference: 25.3 [95% CI -28.9, 79.6]). Among 249 patients with data at week 52, mean (SE) changes in FVC at week 52 were -86.4 (21.1) mL in the placebo group and -39.1 (22.2) mL in the nintedanib group. Among 183 patients with lcSSc who participated in SENSCIS-ON and had data at week 52, mean (SE) changes in FVC from baseline to week 52 of SENSCIS-ON were -41.5 (24.0) mL in patients who took placebo in the SENSCIS trial and initiated nintedanib in SENSCIS-ON and -45.1 (19.1) mL in patients who took nintedanib in the SENSCIS trial and continued it in SENSCIS-ON.
Conclusion: Patients with lcSSc may develop progressive fibrosing ILD. By targeting pulmonary fibrosis, nintedanib slows decline in lung function in patients with lcSSc and ILD.
Details
- Title: Subtitle
- Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease
- Creators
- Yannick AllanoreDinesh Khanna - University of MichiganVanessa SmithMartin AringerAnna-Maria Hoffmann-VoldMasataka KuwanaPeter A MerkelChristian StockSteven SambevskiChristopher P DentonSENSCIS Trial Investigators
- Contributors
- Alicia Gerke (Contributor) - University of Iowa, Pulmonary, Critical Care, and Occupational Medicine
- Resource Type
- Journal article
- Publication Details
- Rheumatology, Vol.63(3), pp.639-647
- DOI
- 10.1093/rheumatology/kead280
- PMID
- 37294870
- PMCID
- PMC10907814
- NLM abbreviation
- Rheumatology (Oxford)
- ISSN
- 1462-0324
- Publisher
- Oxford University Press
- Grant note
- DOI: 10.13039/100008349, name: Boehringer Ingelheim International GmbH
- Language
- English
- Electronic publication date
- 06/09/2023
- Date published
- 03/01/2024
- Academic Unit
- Pulmonary, Critical Care, and Occupational Medicine; Internal Medicine
- Record Identifier
- 9984546840002771
Metrics
4 Record Views